Atossa Genetics Inc. (NASDAQ:ATOS) Receives $6.33 Consensus PT from Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has received a consensus recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.3333.

Several equities analysts recently weighed in on ATOS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday. Ascendiant Capital Markets increased their target price on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Zacks Research lowered shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after purchasing an additional 37,809 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Atossa Genetics during the 2nd quarter valued at $321,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Atossa Genetics in the second quarter worth $49,000. Qube Research & Technologies Ltd raised its position in shares of Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after buying an additional 325,340 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Atossa Genetics in the second quarter worth $381,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Stock Down 1.9%

Shares of NASDAQ:ATOS opened at $0.64 on Friday. The stock has a market cap of $82.94 million, a PE ratio of -2.68 and a beta of 1.09. The business has a 50 day moving average of $0.70 and a 200-day moving average of $0.81. Atossa Genetics has a 12-month low of $0.55 and a 12-month high of $1.29.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). Equities research analysts expect that Atossa Genetics will post -0.22 earnings per share for the current year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.